CO4940466A1 - Sales metanosulfonato de 5-(2-(4-(1,2-benzoisotiazol-3-il)- 1-piperazinil)etil)-6-cloro-1,3-dihidro-2h-indol-2-ona dihidratadas - Google Patents

Sales metanosulfonato de 5-(2-(4-(1,2-benzoisotiazol-3-il)- 1-piperazinil)etil)-6-cloro-1,3-dihidro-2h-indol-2-ona dihidratadas

Info

Publication number
CO4940466A1
CO4940466A1 CO97022872A CO97022872A CO4940466A1 CO 4940466 A1 CO4940466 A1 CO 4940466A1 CO 97022872 A CO97022872 A CO 97022872A CO 97022872 A CO97022872 A CO 97022872A CO 4940466 A1 CO4940466 A1 CO 4940466A1
Authority
CO
Colombia
Prior art keywords
salts
piperazinyl
dihydro
ethyl
benzoisotiazol
Prior art date
Application number
CO97022872A
Other languages
English (en)
Spanish (es)
Inventor
Frank Robert Busch
Anne Rose Carol
Russell James Shine
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of CO4940466A1 publication Critical patent/CO4940466A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Saccharide Compounds (AREA)
CO97022872A 1996-05-07 1997-04-29 Sales metanosulfonato de 5-(2-(4-(1,2-benzoisotiazol-3-il)- 1-piperazinil)etil)-6-cloro-1,3-dihidro-2h-indol-2-ona dihidratadas CO4940466A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1675796P 1996-05-07 1996-05-07

Publications (1)

Publication Number Publication Date
CO4940466A1 true CO4940466A1 (es) 2000-07-24

Family

ID=21778804

Family Applications (1)

Application Number Title Priority Date Filing Date
CO97022872A CO4940466A1 (es) 1996-05-07 1997-04-29 Sales metanosulfonato de 5-(2-(4-(1,2-benzoisotiazol-3-il)- 1-piperazinil)etil)-6-cloro-1,3-dihidro-2h-indol-2-ona dihidratadas

Country Status (40)

Country Link
US (1) US6245765B1 (enExample)
EP (1) EP0918772B1 (enExample)
JP (1) JP3494659B2 (enExample)
KR (1) KR100333215B1 (enExample)
CN (1) CN1091769C (enExample)
AP (1) AP765A (enExample)
AR (1) AR007004A1 (enExample)
AT (1) ATE278689T1 (enExample)
AU (1) AU731267B2 (enExample)
BG (1) BG63544B1 (enExample)
BR (1) BR9709889A (enExample)
CA (1) CA2252898C (enExample)
CO (1) CO4940466A1 (enExample)
CZ (1) CZ289215B6 (enExample)
DE (1) DE69731094T2 (enExample)
DK (1) DK0918772T3 (enExample)
DZ (1) DZ2222A1 (enExample)
EA (1) EA001190B1 (enExample)
EG (1) EG24076A (enExample)
ES (1) ES2229342T3 (enExample)
GT (1) GT199700052A (enExample)
HR (1) HRP970236B1 (enExample)
ID (1) ID16867A (enExample)
IL (1) IL126591A (enExample)
IS (1) IS2080B (enExample)
MA (1) MA24171A1 (enExample)
MY (1) MY119997A (enExample)
NO (1) NO312514B1 (enExample)
NZ (1) NZ332218A (enExample)
OA (1) OA10909A (enExample)
PL (1) PL188330B1 (enExample)
PT (1) PT918772E (enExample)
SI (1) SI0918772T1 (enExample)
SK (1) SK282837B6 (enExample)
TN (1) TNSN97074A1 (enExample)
TR (1) TR199802240T2 (enExample)
TW (1) TW491847B (enExample)
UA (1) UA46840C2 (enExample)
WO (1) WO1997042191A1 (enExample)
ZA (1) ZA973876B (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HN1996000101A (es) * 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
UA57734C2 (uk) 1996-05-07 2003-07-15 Пфайзер Інк. Комплекси включення арилгетероциклічних солей
IL127497A (en) * 1997-12-18 2002-07-25 Pfizer Prod Inc Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders
US20080113025A1 (en) * 1998-11-02 2008-05-15 Elan Pharma International Limited Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
AU2001258690A1 (en) * 2000-06-02 2001-12-11 Pfizer Products Inc. S-methyl-dihydro-ziprasidone for treatment of psychiatric and ocular disorders
US20040048876A1 (en) * 2002-02-20 2004-03-11 Pfizer Inc. Ziprasidone composition and synthetic controls
UY27668A1 (es) * 2002-02-20 2003-10-31 Pfizer Prod Inc Composición de ziprasidona y controles sintéticos
EP1633400A2 (en) * 2003-05-16 2006-03-15 Pfizer Products Inc. Therapeutic combinations of atypical antipsychotics with gaba modulators, anticonvulsants or benzodiazapines
EP1546146A1 (en) 2003-06-03 2005-06-29 Teva Pharmaceutical Industries Limited POLYMORPHIC FORMS OF ZIPRASIDONE HCl AND PROCESSES FOR THEIR PREPARATION
CA2543805A1 (en) 2003-10-24 2005-05-06 Gideon Pilarsky Processes for preparation of ziprasidone
EP1753460A2 (en) * 2004-05-11 2007-02-21 Pfizer Products Inc. Combination of atypical antipsychotics and 5-ht1b receptor antagonists
CA2467538C (en) 2004-05-14 2010-08-24 Apotex Pharmachem Inc. New amorphous ziprasidone hydrochloride (5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride) and processes to produce the same
CA2471219A1 (en) 2004-06-14 2005-12-14 Apotex Pharmachem Inc. Improved preparation of an anhydrate form of 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride (ziprasidone hydrochloride)
US7777037B2 (en) * 2004-10-27 2010-08-17 Dr. Reddy's Laboratories Limited Ziprasidone process
AU2005307797B2 (en) * 2004-11-16 2011-06-02 Alkermes Pharma Ireland Limited Injectable nanoparticulate olanzapine formulations
CA2591670A1 (en) * 2005-02-11 2006-08-17 Teva Pharmaceutical Industries Ltd. Process of preparing ziprasidone mesylate
CA2593497A1 (en) * 2005-02-11 2006-08-17 Judith Aronhime Amorphous ziprasidone mesylate
US20080254114A1 (en) * 2005-03-03 2008-10-16 Elan Corporation Plc Controlled Release Compositions Comprising Heterocyclic Amide Derivative Nanoparticles
ITMI20050346A1 (it) 2005-03-07 2006-09-08 Dipharma Spa Forma solida di ziprasidone cloridrato
CA2500667C (en) 2005-03-11 2013-01-15 Apotex Pharmachem Inc. Preparation of acid addition salts of ziprasidone and intermediates thereof by solid phase-gas phase reactions
EP1858891A2 (en) * 2005-03-14 2007-11-28 Teva Pharmaceutical Industries Ltd. Crystalline forms of ziprasidone mesylate
EP1858892A1 (en) * 2005-03-14 2007-11-28 Teva Pharmaceutical Industries Ltd Anhydrous ziprasidone mesylate and a process for its preparation
ITMI20052216A1 (it) * 2005-11-18 2007-05-19 Dipharma Spa Procedimento per la preparazione di ziprasidone
CN101677568A (zh) * 2007-05-18 2010-03-24 赛多斯有限责任公司 齐拉西酮制剂
EP2321011A1 (en) * 2008-06-25 2011-05-18 Pfizer Inc. Diaryl compounds and uses thereof
CN107595771A (zh) * 2010-10-18 2018-01-19 大日本住友制药株式会社 注射用缓释制剂
SI23610A (sl) 2011-01-13 2012-07-31 Diagen@d@o@o Nove adicijske soli ziprasidona postopek za njihovo pripravo in njihova uporaba v terapiji
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX173362B (es) * 1987-03-02 1994-02-23 Pfizer Compuestos de piperazinil heterociclicos y procedimiento para su preparacion
US4831031A (en) * 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US5206366A (en) * 1992-08-26 1993-04-27 Pfizer Inc. Process for preparing aryl piperazinyl-heterocyclic compounds
US5312925A (en) * 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
US5359068A (en) * 1993-06-28 1994-10-25 Pfizer Inc. Processes and intermediates for the preparation of 5-[2-(4-(benzoisothiazol-3-yl)-piperazin-1-yl)ethyl]-6-chloro-1,3-dihydro-indol-2-one
IL126590A (en) 1996-05-07 2001-11-25 Pfizer Trihydrate salt of -5 (-2 (-4 (1 (2, 2-benzothiazole - 3yl) -1-piperazinyl) ethyl) - 6-chloro-1, 3-dihydro-2 (1H) - indole - 2On (= Ziprasidone) and pharmaceutical preparations containing it

Also Published As

Publication number Publication date
CZ289215B6 (cs) 2001-12-12
SK282837B6 (sk) 2002-12-03
SI0918772T1 (en) 2005-02-28
UA46840C2 (uk) 2002-06-17
ID16867A (id) 1997-11-20
JPH11509867A (ja) 1999-08-31
AU2174797A (en) 1997-11-26
CA2252898C (en) 2003-04-08
TW491847B (en) 2002-06-21
IS4874A (is) 1998-10-20
KR100333215B1 (ko) 2002-06-20
EA199800912A1 (ru) 1999-04-29
PL329884A1 (en) 1999-04-12
MA24171A1 (fr) 1997-12-31
ATE278689T1 (de) 2004-10-15
BG102892A (en) 1999-09-30
AP765A (en) 1999-09-17
OA10909A (en) 2001-10-26
AU731267B2 (en) 2001-03-29
EA001190B1 (ru) 2000-12-25
AP9700976A0 (en) 1997-07-31
PL188330B1 (pl) 2005-01-31
IL126591A0 (en) 1999-08-17
SK150898A3 (en) 2000-02-14
DE69731094T2 (de) 2006-02-23
CN1091769C (zh) 2002-10-02
BG63544B1 (bg) 2002-04-30
NZ332218A (en) 2005-02-25
TR199802240T2 (enExample) 1999-02-22
AR007004A1 (es) 1999-10-13
MY119997A (en) 2005-08-30
PT918772E (pt) 2004-12-31
NO985194L (no) 1998-11-06
NO312514B1 (no) 2002-05-21
HRP970236A2 (en) 1998-06-30
ZA973876B (en) 1998-11-06
NO985194D0 (no) 1998-11-06
DE69731094D1 (de) 2004-11-11
CN1216991A (zh) 1999-05-19
US6245765B1 (en) 2001-06-12
EP0918772A1 (en) 1999-06-02
CA2252898A1 (en) 1997-11-13
HRP970236B1 (en) 2002-12-31
IS2080B (is) 2006-02-15
EG24076A (en) 2008-05-11
BR9709889A (pt) 1999-08-10
GT199700052A (es) 2001-08-29
CZ349398A3 (cs) 1999-09-15
DK0918772T3 (da) 2005-01-10
IL126591A (en) 2001-11-25
TNSN97074A1 (fr) 2005-03-15
KR20000010824A (ko) 2000-02-25
DZ2222A1 (fr) 2002-12-03
EP0918772B1 (en) 2004-10-06
WO1997042191A1 (en) 1997-11-13
HK1017892A1 (en) 1999-12-03
JP3494659B2 (ja) 2004-02-09
ES2229342T3 (es) 2005-04-16

Similar Documents

Publication Publication Date Title
CO4940465A1 (es) Sal mesilato trihidrato de 5-(2-(4-(1,2-benzoisotiazol-3- il)-1-piperazinil)etil)-6-cloro-1,3-dihidro-2h-indol-2-ona
GT199700052A (es) Sales metanosulfonatode5-(2-4-(1,2-benzoisotiazol-3-il)-piperazinil)etil)-6-cloro-1,3-dihidro-2h-indol-2-onadihidratadas
PA8436201A1 (es) Derivados 6,5-heterobiciclicos sustituidos
ES2072627T3 (es) Derivados de piridina y n-oxido de piridina de diarilmetilpiperidinas o piperazinas, composiciones y uso de las mismas.
CO4930259A1 (es) Derivados 6,6-heterobiciclicos sustituidos y composiciones farmaceuticas que los contienen
SV2003000633A (es) Nuevos tiadiazoles y oxadiazoles y su uso como inhibidores de fosfodiesterasa-7
NO982907D0 (no) Tyrosinderivater som <alfa>-v-integrininhibitorer
NO180445C (no) 2-(4-hydroksypiperidino)-1-alkanol-derivater som anti-iskemiske midler
DE60121461D1 (de) Kondensierte pyridoindolderivate
HN2001000235A (es) Derivados puentes de piperazina
ATE219067T1 (de) Substituierte (2-(1-piperazinyl)ethoxy)methyl- derivate
DE60112960D1 (de) Kondensierte pyridoindolderivate
AR020563A1 (es) Compuestos (poli)tia-alquinoicos y sus derivados, composiciones que los incluyen y su utilizacion
MX9704034A (es) Derivados y composiciones de 1,1-dioxido de 2-arilcarboniloximetil-1,2,5-tiadiazolidin-3-ona substituido y metodo de uso.
BR0114380A (pt) Derivados-1-aminobutan-3-ol-substituìdos
NO305082B1 (no) 2-(4-(4-azolbutyl)-1-piperazinyl)-5-hydroksy-pyrimidinderivater, deres fremstilling og anvendelse som legemidler
ES2192789T3 (es) Derivados de hidrazono-benzazuleno, composiciones farmaceuticas y compuestos intermedios.
DK0888340T3 (da) 4-(benzo-1,3-dioxolyl)-pyrrolidin-3-carboxylsyre-derivater som antagonister for enodthelin
AR027349A1 (es) Derivados de amidas heterociclicas
MX9205186A (es) Derivados de 4-[4-[4-(4-hidroxifenil)-1-piperazinil]-fenil]-5-metil-3h-1,2,4-triazo l-3-ona
HN2000000057A (es) Derivados de i - trifluorometil-4-hidroxi-7-piperidinil- aminometilcromano.
IT1289154B1 (it) Derivati di isoflavone loro preparazione e loro impiego terapeutico
ECSP972096A (es) Sales metanosulfanato de 5-[2-[4-[1,2-benzoisotiazol-3- [il] -1 -piperaziniletil]-6-cloro-1,3 2h - indol - 2-ona dihidratas
NO971991D0 (no) Heterosyklus-substituerte propensyrederivater som NMDA-antagonister
ECSP972089A (es) Sal mesilato trihidrato de 5-[2-[4(1,2-benzoisotiazol-3-il]-1-piperazinil)etil]-6-cloro- 1,3- dihidro- 2h- inddol - 2 - ona